RegenLab PRP, the first platelet-rich plasma treatment in Australia, is backed by 112 scientific papers for a myriad of indications.

RegenLab is a global leader in products for autologous regenerative medicine based on freshly prepared PRP taken from a patient’s own blood that is safer and has longer lasting effects than traditional cell-therapy products.

It offers accelerated healing and proven efficacy in ageing management, wound care and musculoskeletal pathologies.

With the recent flurry of media focus on and government warnings about unsafe and illegal practices at beauty and cosmetic clinics, now more than ever doctors need to ensure S4 medications and devices are TGA registered and backed by clinical evidence supporting their efficacy and safety.

RegenLab PRP is one such technology, backed by 112 scientifc papers for a myriad of indications; from the treatment of many medical problems (eg. osteopathic conditions), during major surgeries such as transplants and burns treatments, ulcer healing, bone grafts, musculoskeletal injuries, cardiac surgeries, vulvo-vaginal repair and rejuvenation, and hair regrowth.

It has been used in aesthetic medicine in the UK, Asia and Europe to rejuvenate and slow down the ageing process since 2006 and was approved for use in Australia in January 2009, where it has remained at the forefront of anti-ageing technology.

RegenLab PRP enhances facial volume, plumps and fills in fine lines and wrinkles, promotes a more youthful and radiant complexion and can be successfully utilised in the delicate areas around the eyes and mouth, where dermal fillers, lasers and neurotoxins may not be as effective.

Although there are several PRP systems on the market today, RegenLab PRP has a unique centrifugation process.

Designed to yield the optimal concentration of blood platelets, it gives physicians the option to increase the platelet concentration to four times the patient’s baseline if required.

Typically, eight to 24ml of blood is collected in one or two RegenLab PRP tubes. During centrifugation, a patented gel within the tubes isolates PRP from other unrequired cells (platelet-poor plasma and red blood cells).

No additional manipulations or incubations of the patient’s PRP occur. Comparative studies show that RegenLab PRP has an exceptionally high platelet yield of above 90 per cent.

Other systems range from 40 to 60 per cent, meaning they require more blood to be drawn from the patient so that PRP can be produced at the optimal concentration for skin rejuvenation.

RegenLab is a Swiss company that specialises in PRP and cell therapy. Its philosophy can be summed up as: Safety, Quality, Efficiency.

`It is important for doctors to use an approved medical device, certified for platelet rich plasma preparation,’ says Solange Vischer, product manager for RegenLab in Switzerland.

This is not only to respect good medical practices and to meet the requirements of the TGA but mainly to ensure the safety of the patient and the operator, and guarantee the clinical e cacy of the resulting product.

`RegenLab PRP is manufactured in respect of international norms and regulations in a facility in Switzerland that has more than 1000 square metres of clean rooms under controlled atmosphere.

`The system works in full closed circuit, thus with no risk of bacterial contamination for the patient or blood exposure for the operator. Blood is directly and automatically collected in the device, with no exposure to air that would generate oxidative stress.

`The anticoagulant is pre-dosed in the device, so with no risk of product error or wrong dosage.

`This anticoagulant is at pH 7, is isotonic, has no ancillary e ect on the patient and is fully reversible. Its action ceases as soon as the PRP is injected in tissues.

`The devices contain a separating gel speci cally designed for optimal platelet isolation. The gel is biologically inert, thus doesn’t interact with blood. During the preparation process, it migrates in the device and intercalate itself precisely between blood components.

At the end of centrifugation, it forms a solid mechanical barrier that sequestrate the red and white blood cells in the lower part of the device while the platelets and the plasma can easily be recovered from the upper part of the device.


Learn about PRP and innovative advancements in its applications at the1st BIOBRIDGE Asia-Paci c conference: Shangri-la Hotel, Sydney, 23-24 February 2018 – includes Sydney Harbour cruise dinner.

There are two dedicated rooms, one showcasing the latest developments in Musculoskeletal Medicine, Sports Medicine and Pain Medicine and the other for Aesthetic and Cosmetic Medicine.

Day 1: Literature review and proven uses for PRP
Day 2: Live workshops


Main speakers
Dr Patrick Goh,
Sports Medicine, Singapore
Dr Stanley Lam,
Musculoskeletal Pain Management
and Sports Injury, Hong Kong
Dr Li Pan,
Musculoskeletal Pain Management
and Sports Injury, Taiwan
Dr Phillipe Macaire,
Anaesthetist, France/Vietnam
Dr Wesley Chen,
Musculoskeletal Medicine, Taiwan
Dr Philip Lim,
Physical Medicine, Australia
Dr Jeni Saunders,
Sports and Exercise Medicine, Australia
Dr Marc Russo,
Pain Management, Australia


Main speakers
Dr Ksenija Martinec,
Gynaecology, Slovenia
Dr Stephen Low and RN Nicole Belle,
Cosmetic Medicine, Australia
Dr Ronald Feiner,
Cosmetic Medicine, Australia
Dr Joseph Ajaka,
Cosmetic Surgery, Australia
Dr Xiao Wu,
Cosmetic Surgery, Australia
Dr Robin Chok,
Cosmetic Surgery, Australia
Dr Fariba Willison,
Gynaecology, Australia

REGISTER event/1st-biobridge-asia-paci c-conference/


RegenLab PRP is backed by 112 scientific papers for a myriad of indications. Following are some recent examples. For access to all papers, visit


An economic evaluation of PRP versus hyaluronic acid for the treatment of knee osteoarthritis [HA being the standard therapy for drug-resistant OA that does not benefit or has short term benefits ( Conclusion: “In the short term, it seems that the PRP therapy is cost-effective in the treatment of knee OA versus the HA therapy. However, more research is needed to assess its cost-e ectiveness in the long term and to gure out if this treatment may be an e cient resource allocation for the [Italian national health system].”


From March 2014 to June 2015, 30 patients with atrophic acne scars on the cheeks were selected for a comparative study using autologous fat grafts plus PRP with or without fractional CO2 laser resurfacing.

The study was conducted by Tenna, Cogliandro, Barone, Panasiti, Tirindelli, Nobile and Persichetti, variously of the Unit of Plastic Reconstructive and Aesthetic Surgery and Dermatology, and Department of Ematology, University of Rome. Their conclusions were published on (US National Library of Medicine and National Institutes of Health) in June, 2017.

All patients were treated with in ltration of nanofat plus PRP. The production of PRP was achieved using the RegenLab THT tube method.

Patients were evaluated pre- and post-operatively by physical examination, photographs and ultrasound with a 22-MHz probe to measure subcutaneous tissue thickness.
In 15 randomly chosen patients (group B), a fractional CO2 laser resurfacing at 15 W was also performed right after the infiltration.

An Italian version of the FACE-Q post-operative module was administered to analyse each patient’s satisfaction and aesthetic perception of the result.

Results: The average pre- operative thickness of subcutaneous tissue of patients from group A was 0.532cm, and 0.737cm in group B.

All patients in both groups had a treatment bene t, con rmed with FACE-Q post-operative module, but without a signi cant di erence between the two groups.

Conclusion: Subcutaneous in ltration with nanofat and PRP seems to be e ective to improve atrophic scars, either alone or combined with fractional CO2 laser resurfacing. The FACE-Q module con rmed the impact of treatment of facial acne scars in social life and relationships.


A novel technique of vulvo- vaginal rejuvenation by lipo lling and injection of combined PRP and hyaluronic acid has been developed by Aguilar, Hersant, SidAhmed-Mezi, Bosc , Vidal and Meningaud at the Department of Plastic, Reconstructive and Aesthetic Surgery, Henri Mondor Hospital, Créteil, France.

Abstract: ‘There are no standard non-invasive treatments to o er to improve the trophic
and dimensional alterations of the vulvo-vaginal area,’ according to the researchers’ ndings published on

‘The surgical procedure consists in a vaginoplasty by lipo lling of the posterior vaginal wall far from the vascular axes and with an injection of an injection of combined PRP and HA subcutaneously in the perineum.

To illustrate the technique and evaluate its results, we present the case of a 39-year-old female with history of episiotomy presented that vaginal laxity resistant to physical therapy.

Findings: ‘There were no intra-operative complications with this simple procedure. During follow-up we observed an improvement in the modi ed Stabbatsberg scale and a vulvo-perineal rejuvenation by improving the vaginal trophicity and restoring a normal vaginal caliber. No post-operative complications occurred.’

Conclusion: ‘[It] is a minimally invasive technique that is safe and easy to perform.’


A study of PRP injections in the treatment of androgenetic alopecia through an one-year period was conducted by Gkini, Kouskoukis, Tripsianis, Rigopoulos and Kouskoukis at the Department of Dermatology and Venereology, Medical School, and Laboratory of Medical Statistics, Democritus University of Thrace, Alexandroupolis, Greece; and the Department of Dermatology and Venereology, Medical School, Attikon Hospital, University of Athens.

Method: Twenty patients, 18 males and two females, with androgenetic alopecia were enrolled in the study. PRP was prepared using a single spin method (Regenlab SA). Upon activation, it was injected in the androgen-related areas of scalp. Three treatment sessions were performed with an interval of 21 days and a booster session at six months following the onset of therapy.

Statistical analysis of the data was performed using the Statistical Package for the Social Sciences (SPSS), version 19.0 (IBM, NY, US).

Results: Hair loss reduced and at three months it reached normal levels. Hair density reached a peak at three months (170.70 ± 37.81, P < 0.001). At six months and at one year, it was signi cantly increased, 156.25 ± 37.75 (P < 0.001) and 153.70 ± 39.92 (P < 0.001) respectively, comparing to baseline. Patients were satis ed with a mean result rating of 7.1 on a scale of one to 10. No remarkable adverse effects were noted.

For more information
call RegenLab PRP
on 02 9496 1426
or visit



Previous articleLand of milk and honey
Next articleAesthetic Medical Practitioner #12